eCite Digital Repository

ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases

Citation

Ding, C and Xu, J and Li, J, ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases, Current Opinion in Investigational Drugs, 9, (5) pp. 515-522. ISSN 1472-4472 (2008) [Refereed Article]

Abstract

ABT-874, a fully human mAb that blocks the binding of IL-12 and IL-23 to their shared IL-12 receptor β1, is currently being developed by Abbott Laboratories for the potential treatment of Crohn's disease and psoriasis. The compound is currently in phase III clinical trials for psoriasis and phase II trials for Crohn's disease. ABT-87 was previously being developed for the potential treatment of multiple sclerosis; however, by May 2007, development for this indication was discontinued. © The Thomson Corporation.

Item Details

Item Type:Refereed Article
Research Division:Medical and Health Sciences
Research Group:Clinical Sciences
Research Field:Rheumatology and Arthritis
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Skeletal System and Disorders (incl. Arthritis)
Author:Ding, C (Professor Chang-Hai Ding)
ID Code:54879
Year Published:2008
Web of Science® Times Cited:31
Deposited By:Menzies Institute for Medical Research
Deposited On:2009-03-02
Last Modified:2009-04-25
Downloads:0

Repository Staff Only: item control page